{"version": "https://jsonfeed.org/version/1.1", "title": "Sharemaestro Newsreel: Portugal Paper & Paper Products news", "home_page_url": "https://sharemaestro.com/newsreel/pt/basic-materials/paper-paper-products/", "feed_url": "https://sharemaestro.com/newsreel/pt/basic-materials/paper-paper-products/feed.json", "description": "Latest Paper & Paper Products company headlines from Portugal, newest first, with source links and direct routes to company research and sentiment.", "language": "en", "items": [{"id": "source:42a629e691055a42ec13ef8bc6f0f3c3d31f7b2c7e8038507a15807a75e34ff2", "url": "https://finance.yahoo.com/healthcare/articles/market-chatter-novartis-wins-uk-153302721.html", "external_url": "https://finance.yahoo.com/healthcare/articles/market-chatter-novartis-wins-uk-153302721.html", "title": "Update: Market Chatter: Novartis Wins UK Court Challenge to Entresto Patent", "content_text": "(Updates with response from a Novartis spokesperson in the fourth and fifth paragraphs.)Novartis (NVS) defeated a bid by Accord Healthcare to invalidate its Entresto patent, with a UK court ruling that the patent and a related protection certificate remain valid, Reuters reported Silver Upgrade to read this MT Newswires article and get so much more. A Silver or Gold subscription plan is required to access premium news articles. Upgrade now", "date_published": "2026-08-13T15:33:02+00:00", "authors": [{"name": "finance.yahoo.com"}], "tags": ["Analyst action", "NVG"], "_sharemaestro": {"country": "Portugal", "coverage": "Provider-linked mention", "market_context": null, "companies": [{"symbol": "NVG", "name": "The Navigator Company, S.A.", "sentiment_url": "https://sharemaestro.com/sentiment/88350c74-100d-49b1-848a-897c4897ecb2/"}]}}, {"id": "source:925017f4be8893e31a12586289c34f0c7ee514ff04b91b00d8b70dac2f840033", "url": "https://finance.yahoo.com/energy/articles/cez-xpra-cez-q2-2026-011013959.html", "external_url": "https://finance.yahoo.com/energy/articles/cez-xpra-cez-q2-2026-011013959.html", "title": "CEZ AS (XPRA:CEZ) (Q2 2026) Earnings Call Highlights: Net Income Rises 10% as Windfall Tax ...", "content_text": "This article first appeared on GuruFocus. Revenue: Operating revenue decreased 5% year-on-year, primarily due to lower power prices. EBITDA: Down 20% to CZK59 billion, impacted by lower generation prices and reduced trading profits. Net Income: Increased 10% to CZK18.1 billion, driven by the absence of the windfall profit tax, which ended on December 31, 2025. Operating Cash Flow: Increased by CZK26 billion, or 55% year-on-year. Capital Expenditures (CapEx): Increased 30% year-on-year. Net Debt: Approximately 9% higher, approaching CZK200 billion. Generation and Mining EBITDA: Decreased by CZK14.5 billion, or 31%, due to lower power prices. Coal Generation EBITDA: Down 65% to CZK1.4 billion, despite similar production volumes. Distribution EBITDA: Increased by CZK2 billion, or 10%, with normalized electricity EBITDA up 15% and gas distribution normalized EBITDA up 25%. Sales Segment EBITDA: Decreased by CZK2.4 billion, partly due to lower margins in retail and wholesale. Income Tax: Fell to CZK5.5 billion from CZK23.1 billion, reflecting the removal of the windfall profit tax. Guidance (EBITDA): Raised to CZK109 billion to CZK114 billion from CZK107 billion to CZK112 billion. Guidance (Adjusted Net Income): Raised to CZK31 billion to CZK35 billion from CZK30 billion to CZK34 billion. Nuclear Generation: 15.3 terawatt-hours generated in the first half, with a full-year target of 30.6 terawatt-hours. Fossil Fuel Generation: Up 6% in the first half, with full-year coal generation expected to increase 9% and natural gas by 87%. Hedging: 76% hedged for 2027 at an average price of EUR88 per megawatt-hour. Warning! GuruFocus has detected 9 Warning Signs with XPRA:CEZ. Is XPRA:CEZ fairly valued? Test your thesis with our free DCF calculator. Release Date: August 11, 2026 For the complete transcript of the earnings call, please refer to the full earnings call transcript. Positive Points Net income increased 10% year-on-year to CZK18.1 billion, driven by the end of the windfall tax. Operating cash flow rose 55% to CZK26 billion, providing strong liquidity. Distribution segment EBITDA grew 10%, with normalized electricity EBITDA up 15% and gas up 25%. Nuclear generation exceeded expectations, with 15.3 TWh produced in H1 and full-year guidance raised. Guidance for 2026 EBITDA and adjusted net income was raised by CZK2 billion and CZK1 billion, respectively. Negative Points EBITDA declined 20% to CZK59 billion, primarily due to lower power prices. Generation and mining segment EBITDA fell 31%, with coal EBITDA down 65%. Sales segment EBITDA decreased by CZK2.4 billion, impacted by lower margins and project delays. Trading profits were lower, with a negative revaluation of derivatives of CZK2.6 billion. Net debt increased 9% to nearly CZK200 billion, raising leverage concerns. Story Continues Q & A Highlights Q: Can you elaborate on the trading results, which were negatively impacted by derivative revaluations, and discuss the risk of windfall taxes being reintroduced given the current high power prices?A: Pavel Cyrani (Vice Chairman, Head of Sales and Strategy) explained that most of the trading effect is due to intra-year revaluation of energy contracts, which can swing between positive and negative (e.g., +CZK2.6 billion at the end of Q1 vs. -CZK2.6 billion now). He noted that 2026 is a slower year for base trading but expects a recovery to standard levels. Martin Novak (CFO) stated that windfall tax reintroduction is not on the table, as energy company profits are significantly lower than when the tax was introduced, and such a move would impair discussions about new projects and the CEZ Energy separation. Q: What is driving the positive performance in the Distribution segment, and how should we read across to 2027 regarding correction factors?A: Pavel Cyrani (Vice Chairman, Head of Sales and Strategy) attributed the outperformance to higher-than-expected consumption due to a colder winter and underlying recovery in industrial and hous", "date_published": "2026-08-13T01:10:13+00:00", "authors": [{"name": "finance.yahoo.com"}], "tags": ["Market update", "SEM"], "_sharemaestro": {"country": "Portugal", "coverage": "Provider-linked mention", "market_context": null, "companies": [{"symbol": "SEM", "name": "Semapa - Sociedade de Investimento e Gest\u00e3o, SGPS, S.A.", "sentiment_url": "https://sharemaestro.com/sentiment/c94a5a2f-0457-484b-8782-9aac0956200e/"}]}}, {"id": "source:75002d510a976d8fb1fd26d66ac0ca94ee02132e471459632ecb609c35c42bda", "url": "https://finance.yahoo.com/technology/ai/articles/gft-technologies-se-wbo-gft-010536877.html", "external_url": "https://finance.yahoo.com/technology/ai/articles/gft-technologies-se-wbo-gft-010536877.html", "title": "GFT Technologies SE (WBO:GFT) (H1 2026) Earnings Call Highlights: AI-Driven Growth and ...", "content_text": "This article first appeared on GuruFocus. Revenue: EUR462.6 million in H1 2026, a 5% increase in both euros and constant currencies. Adjusted EBIT: EUR33 million, up 8% year-over-year, with a margin of 7.1% compared to 6.8% in H1 2025. EBT: EUR24 million, up 26% year-over-year, with the EBT margin improving from 4.3% to 5.2%. Q2 Revenue: EUR233.04 million, a 6% increase versus Q2 2025. Q2 Adjusted EBIT: EUR16.5 million, a 10% increase versus Q2 2025. Order Backlog: Up 18% versus last year. Wynxx Soft Engineering Revenue: EUR24.4 million in actual influenced revenue in H1 2026. Wynxx Business Process Revenue: EUR14.8 million in actual influenced revenue in H1 2026. Wynxx Total Influenced Contract Value: Over EUR144 million since inception, representing 38% growth quarter-over-quarter. Operating Cash Flow: Minus EUR1 million, an improvement from minus EUR9 million in the prior year. Free Cash Flow (Adjusted): Improved to minus EUR8.3 million from minus EUR17.3 million a year ago. Employees: 11,805 at the end of June, flat versus the beginning of the year and up 3% versus June last year. Utilization Rate: Increased to 92.8%. Attrition: Reduced to 10.4%. Warning! GuruFocus has detected 7 Warning Sign with WBO:GFT. Is WBO:GFT fairly valued? Test your thesis with our free DCF calculator. Release Date: August 06, 2026 For the complete transcript of the earnings call, please refer to the full earnings call transcript. Positive Points GFT Technologies SE (WBO:GFT) reported solid revenue growth of 5% in H1 2026, with strong performance in key markets like Brazil (38%), Colombia (27%), Switzerland (22%), and Spain (13%). Profitability improved significantly, with adjusted EBIT up 8% to EUR33 million and EBT up 26% to EUR24 million, reflecting better earnings quality and disciplined execution. The Wynxx Agentic AI platform is scaling rapidly, with 113 clients, 12 countries, and total influence contract value reaching EUR144 million, up 38% quarter-over-quarter. The company won six next-generation core banking programs and a major AML platform go-live for a Tier 1 European bank, demonstrating strong domain expertise and client trust. The order backlog increased by 18%, driven by multi-year contracts, including SAP business in Brazil, providing strong visibility for future growth. Negative Points Revenue in Germany declined by 12% due to investment caution, and the UK business was down 18% in H1, though expected to return to growth in Q3. North America revenue declined 7% due to a low-margin pass-through business in Canada and unfavorable FX, with Canada down 12% in euro terms. Operating cash flow was negative at EUR1 million in H1, reflecting seasonality and working capital tied up in contract assets, though improved from last year. The company faces headwinds from FX in North America, which could impact revenue, though offset by tailwinds in Latin America. Internal AI token costs are rising, with an expected spend of around EUR1 million this year, requiring careful management and pricing adjustments. Story Continues Q & A Highlights Q: Can you provide a bridge for the adjusted EBIT guidance, specifically what to expect for M&A and capacity adjustments in H2, and what needs to happen to reach the 7.6% full-year margin from the 7.1% seen in H1? A: Jochen Ruetz (CFO): We expect FX-adjusted EBIT to be roughly flat in the second half. Capacity adjustments should be similar to H1, around EUR3.5 million. To reach the full-year margin, we will repeat the pattern of the last few years, with a stronger second half driven by more billable days, especially in South America. We expect a logical second-half margin of roughly 8% to achieve the overall guidance. Q: Where do you see the market cycle for bank-related IT services, and is sentiment improving? Also, did the six next-gen core banking projects significantly contribute to the strong order backlog growth? A: Marco Santos (CEO): We see improving sentiment among financial services clients, particul", "date_published": "2026-08-13T01:05:36+00:00", "authors": [{"name": "finance.yahoo.com"}], "tags": ["Market update", "SEM"], "_sharemaestro": {"country": "Portugal", "coverage": "Provider-linked mention", "market_context": null, "companies": [{"symbol": "SEM", "name": "Semapa - Sociedade de Investimento e Gest\u00e3o, SGPS, S.A.", "sentiment_url": "https://sharemaestro.com/sentiment/c94a5a2f-0457-484b-8782-9aac0956200e/"}]}}, {"id": "source:ea7e7c83c69cf0488590973f55b3e45a00e458be651cdf2ada60e1789a419701", "url": "https://finance.yahoo.com/technology/articles/sbo-strengthens-position-3d-metal-211539467.html", "external_url": "https://finance.yahoo.com/technology/articles/sbo-strengthens-position-3d-metal-211539467.html", "title": "SBO Strengthens Position in 3D Metal Printing: Expanded Capacity in the US and the UK, Award for 3T", "content_text": "TERNITZ, AUSTRIA - August 11, 2026 (NEWMEDIAWIRE) - SBO AG, listed on the leading index ATX of the Vienna Stock Exchange, is expanding its 3D metal printing capacity in the US and the UK and strengthening its market position in Europe through an award for its subsidiary 3T. Both steps advance SBO's diversification strategy in the growing additive manufacturing market. In the US, SBO has expanded additive manufacturing capacity by adding one VELO XC and two Renishaw 500Q printers for high-performance alloys Inconel and Titanium in Q2 2026. In addition, two more VELO XC printers have been ordere", "date_published": "2026-08-11T21:15:39+00:00", "authors": [{"name": "finance.yahoo.com"}], "tags": ["Market update", "NVG"], "_sharemaestro": {"country": "Portugal", "coverage": "Provider-linked mention", "market_context": null, "companies": [{"symbol": "NVG", "name": "The Navigator Company, S.A.", "sentiment_url": "https://sharemaestro.com/sentiment/88350c74-100d-49b1-848a-897c4897ecb2/"}]}}, {"id": "source:307c68c8377bcf013ad783581ce907b734df56f45e0558685346ed0bf0510ade", "url": "https://finance.yahoo.com/healthcare/articles/regn-soars-21-9-month-143000494.html", "external_url": "https://finance.yahoo.com/healthcare/articles/regn-soars-21-9-month-143000494.html", "title": "REGN Soars 21.9% in a Month: Buy, Sell or Hold the Stock?", "content_text": "The going has been strong for Regeneron Pharmaceuticals REGN over the past month. Shares of this biotech giant have surged 21.9% over the said time frame, outpacing the industry's growth of 4%. The stock has also outperformed the sector and the S&P 500 Index during this time. REGN's robust rally has been driven by better-than-expected quarterly results, which can be attributed to robust demand for Eylea HD (higher dose of Eylea) and higher profit-sharing from Dupixent that helped the company mitigate the decline in Eylea sales. REGN Outperforms Industry, Sector and S&P 500 IndexZacks Investment Research Image Source: Zacks Investment Research Against this backdrop, a closer evaluation of the company's strengths and weaknesses can help assess its attractiveness as an investment opportunity. REGN's Eylea HD Gains Traction as Eylea Sales Decline While lead drug Eylea continues to face headwinds, Eylea HD is gaining traction, supported by steady label expansions. Eylea is an anti-VEGF therapy approved across multiple ophthalmology indications. Declining sales of this drug continue to pressure the company's overall revenues. Competitive pressure has intensified, particularly from Roche's RHHBY Vabysmo, which targets both angiopoietin-2 (Ang-2) and VEGF-A pathways and has gained meaningful traction in the retinal disease market. RHHBY's Vabysmo sales grew 8% to CHF 2 billion in the first half of 2026 on continued global growth. To combat the decline in Eylea sales, Regeneron introduced Eylea HD, a higher-dose formulation of Eylea designed to improve durability and extend dosing intervals, Eylea HD sales in the United States surged 52% year over year to $596 million in the second quarter of 2026, driven by strong uptake following recent FDA label expansions and growing physician confidence in its differentiated profile and flexible dosing regimen. In April 2026, the FDA approved the extension of dosing intervals for Eylea HD to up to every 20 weeks (5 months) for patients with wet age-related macular degeneration (wAMD) and diabetic macular edema (DME) following a year of successful response based on visual and anatomic outcomes. The regulatory body had earlier approved Eylea HD for the treatment of macular edema following retinal vein occlusion (RVO), with dosing of up to once every eight weeks after an initial monthly dosing phase. The FDA also approved a monthly dosing option for certain patients who may benefit from resuming this dosing schedule across all currently approved indications, including wet age-related macular degeneration, DME, diabetic retinopathy and RVO. Story Continues Eylea and Eylea HD were co-developed with Bayer BAYRY. Regeneron records net product sales in the United States, while Bayer records sales outside the country. It expects a further decline in Eylea sales in the second half of 2026 due to ongoing conversion to Eylea HD and increasing competition as multiple biosimilar versions enter the U.S. market. Strong Dupixent Sales Fuel REGN Profits REGN's top line also comprises its share of profits/losses in connection with the global sales of Dupixent. Partner Sanofi records global net product sales of Dupixent. Dupixent continues to deliver strong growth across key indications, including atopic dermatitis, asthma, nasal polyps and eosinophilic esophagitis, while newer uses such as COPD, chronic spontaneous urticaria, bullous pemphigoid and allergic fungal rhinosinusitis are gaining traction. Ongoing label expansions for Dupixent remain a key contributor to revenue visibility and profitability. Regeneron Strengthens Its Oncology Portfolio Regeneron's oncology franchise is anchored by its PD-1 inhibitor Libtayo (cemiplimab-rwlc), which is approved for use in certain patients with advanced basal cell carcinoma (BCC), advanced cutaneous squamous cell carcinoma (CSCC) and advanced non-small cell lung cancer (NSCLC). Libtayo sales continue to be robust, driven by strength across non-melanoma skin cancers and NSCL", "date_published": "2026-08-11T14:30:00+00:00", "authors": [{"name": "finance.yahoo.com"}], "tags": ["Market update", "SEM"], "_sharemaestro": {"country": "Portugal", "coverage": "Provider-linked mention", "market_context": null, "companies": [{"symbol": "SEM", "name": "Semapa - Sociedade de Investimento e Gest\u00e3o, SGPS, S.A.", "sentiment_url": "https://sharemaestro.com/sentiment/c94a5a2f-0457-484b-8782-9aac0956200e/"}]}}, {"id": "source:1b6c75608c039ae482a7ea81916f849cb9c4e0afc0e1f524284fa77b627dde47", "url": "https://finance.yahoo.com/markets/stocks/articles/storebrand-europe-index-announcement-prospectus-072500902.html", "external_url": "https://finance.yahoo.com/markets/stocks/articles/storebrand-europe-index-announcement-prospectus-072500902.html", "title": "Storebrand Europe Index - announcement of prospectus", "content_text": "Storebrand Asset Management AS Lysaker, 10 August 2026 Storebrand hereby announces the Prospectus with Articles of Association Appendix to the Prospectus (\"till\u00e6g\" relevant to Danish investors) for Storebrand Europe Index, an index aware equity fund. The fund has been accepted for listing at Nasdaq Copenhagen and is scheduled for trading on Wednesday 12 August 2026. At end of business on 7 August 2026 the fund had the following diversification characteristics for the shareclass to be listed, Storebrand Europe Index A5 \u2013 ISIN NO0013711408: Total net assets (\"Formue\"): DKK 135.524,10 Outstanding", "date_published": "2026-08-10T07:25:00+00:00", "authors": [{"name": "finance.yahoo.com"}], "tags": ["Market update", "NVG"], "_sharemaestro": {"country": "Portugal", "coverage": "Provider-linked mention", "market_context": null, "companies": [{"symbol": "NVG", "name": "The Navigator Company, S.A.", "sentiment_url": "https://sharemaestro.com/sentiment/88350c74-100d-49b1-848a-897c4897ecb2/"}]}}, {"id": "source:f6a9335814afcde5c73202752c853b1b0a635341fd58878a8f8a66f24f49d1bc", "url": "https://news.google.com/rss/articles/CBMie0FVX3lxTE4wNzRaNXpDd3RNUEhJWHRFRTFaUkFZbW5QR0VIRjI1dkNaQXNXZmdlV19xZTdMVTM0WHd3Tm8zdUFralRtc3h4RlFmVHVDV2pSOEJNV1VvaGpjcnlIZXk2Nkwxb1JKeXpsWDdxZnhPd3hTNlhDWENOMkFndw?oc=5", "external_url": "https://news.google.com/rss/articles/CBMie0FVX3lxTE4wNzRaNXpDd3RNUEhJWHRFRTFaUkFZbW5QR0VIRjI1dkNaQXNXZmdlV19xZTdMVTM0WHd3Tm8zdUFralRtc3h4RlFmVHVDV2pSOEJNV1VvaGpjcnlIZXk2Nkwxb1JKeXpsWDdxZnhPd3hTNlhDWENOMkFndw?oc=5", "title": "Previs\u00e3o ALTR \u2014 Pre\u00e7o Alvo para 2027", "content_text": "Previs\u00e3o ALTR \u2014 Pre\u00e7o Alvo para 2027", "date_published": "2026-06-25T23:39:36+00:00", "authors": [{"name": "TradingView"}], "tags": ["Market update", "ALTR"], "_sharemaestro": {"country": "Portugal", "coverage": "Main company", "market_context": null, "companies": [{"symbol": "ALTR", "name": "Altri, SGPS, S.A.", "sentiment_url": "https://sharemaestro.com/sentiment/6f7fbed2-d7af-4b80-b6a0-d133915d8c46/"}]}}, {"id": "source:cac71fd93fc591e9de2f431840f4b0b3d79d669dce6cbe9529d25676fba947c1", "url": "https://news.google.com/rss/articles/CBMizwFBVV95cUxNUlA3QWRfVVZLYzRlcDVNaE9FMHVJUGNpMnpFUllMYnMyZHR6cUNlQnpIRWpzQXJZNm9ESHo4VzJFNEc0VTJJVUQ5Q2lvS1lTV09kT3J1MnF6Y1NWRVEzN2ZIZkMtN2Y4dEtkUnNNd18yS2tNOEZJbzNqcldHblp5cFowUEtKN1o5R3dNZHhNcXhabDV3UmxGTmRPN2Y4ajE5elRucEw3eG4xYWdNdENyYU1qQU1iMHF3WFh3a0Z6WGVmdDE5ODk2bGt6QVVSdmM?oc=5", "external_url": "https://news.google.com/rss/articles/CBMizwFBVV95cUxNUlA3QWRfVVZLYzRlcDVNaE9FMHVJUGNpMnpFUllMYnMyZHR6cUNlQnpIRWpzQXJZNm9ESHo4VzJFNEc0VTJJVUQ5Q2lvS1lTV09kT3J1MnF6Y1NWRVEzN2ZIZkMtN2Y4dEtkUnNNd18yS2tNOEZJbzNqcldHblp5cFowUEtKN1o5R3dNZHhNcXhabDV3UmxGTmRPN2Y4ajE5elRucEw3eG4xYWdNdENyYU1qQU1iMHF3WFh3a0Z6WGVmdDE5ODk2bGt6QVVSdmM?oc=5", "title": "Lucro da The Navigator Company recua 49,6% em 2025", "content_text": "Lucro da The Navigator Company recua 49,6% em 2025", "date_published": "2026-02-20T08:00:00+00:00", "authors": [{"name": "XTB.com"}], "tags": ["Market update", "NVG"], "_sharemaestro": {"country": "Portugal", "coverage": "Main company", "market_context": null, "companies": [{"symbol": "NVG", "name": "The Navigator Company, S.A.", "sentiment_url": "https://sharemaestro.com/sentiment/88350c74-100d-49b1-848a-897c4897ecb2/"}]}}, {"id": "source:83be1b2c887e06d89cf9c60cd1c5c666b750d27f72e6a8902ad9cc0c2ea12f2b", "url": "https://news.google.com/rss/articles/CBMiVkFVX3lxTE1aZ2RtRVo1Z1cwRnNhdnp1ZkJqZHJ0UTFyMW1oODVVSk1WNktuWkZ0UHRJUGtlTE9SR2ktVkNYNlVXSXE3eG8xYzhYRmV6SHpiTDY5Yjl3?oc=5", "external_url": "https://news.google.com/rss/articles/CBMiVkFVX3lxTE1aZ2RtRVo1Z1cwRnNhdnp1ZkJqZHJ0UTFyMW1oODVVSk1WNktuWkZ0UHRJUGtlTE9SR2ktVkNYNlVXSXE3eG8xYzhYRmV6SHpiTDY5Yjl3?oc=5", "title": "Altri SGPS SA (ALTR.LS) Cota\u00e7\u00e3o das A\u00e7\u00f5es, Not\u00edcias e Previs\u00f5es dos Analistas", "content_text": "Altri SGPS SA (ALTR.LS) Cota\u00e7\u00e3o das A\u00e7\u00f5es, Not\u00edcias e Previs\u00f5es dos Analistas", "date_published": "2024-12-28T04:42:50+00:00", "authors": [{"name": "eToro"}], "tags": ["Market update", "ALTR"], "_sharemaestro": {"country": "Portugal", "coverage": "Main company", "market_context": null, "companies": [{"symbol": "ALTR", "name": "Altri, SGPS, S.A.", "sentiment_url": "https://sharemaestro.com/sentiment/6f7fbed2-d7af-4b80-b6a0-d133915d8c46/"}]}}, {"id": "source:8d8670d4e8d9a22c4dfacd1d1398b58f829f3ece5d542490d30ad672c77474dc", "url": "https://news.google.com/rss/articles/CBMibEFVX3lxTE5XQmo1c3JtX2RJNDV5SkEtanhxQ3VaS0pWNWdNYUYyWnVDQ0g4LWlxLXFoSmVQQ011UHROUmlTX0VmV2FhRlBaSXpQaHF4RGVsUmR4eHU1UmFJUXJXTjJvYnBVb3lIbFhoQmxISg?oc=5", "external_url": "https://news.google.com/rss/articles/CBMibEFVX3lxTE5XQmo1c3JtX2RJNDV5SkEtanhxQ3VaS0pWNWdNYUYyWnVDQ0g4LWlxLXFoSmVQQ011UHROUmlTX0VmV2FhRlBaSXpQaHF4RGVsUmR4eHU1UmFJUXJXTjJvYnBVb3lIbFhoQmxISg?oc=5", "title": "An\u00e1lise t\u00e9cnica do Altri, SGPS, S.A. (EURONEXT:ALTR)", "content_text": "An\u00e1lise t\u00e9cnica do Altri, SGPS, S.A. (EURONEXT:ALTR)", "date_published": "2018-02-08T19:48:03+00:00", "authors": [{"name": "TradingView"}], "tags": ["Market update", "ALTR"], "_sharemaestro": {"country": "Portugal", "coverage": "Main company", "market_context": null, "companies": [{"symbol": "ALTR", "name": "Altri, SGPS, S.A.", "sentiment_url": "https://sharemaestro.com/sentiment/6f7fbed2-d7af-4b80-b6a0-d133915d8c46/"}]}}, {"id": "source:63446380caea3a8f3ce8e2b7ef0b4422f02977ed9459b0dd53f8fedbd84552b3", "url": "https://news.google.com/rss/articles/CBMia0FVX3lxTFBxTm5UWlFEUTl5MENWWmZpNUEzV19NUzhMRWRNc2p1ckJSUEpMTEF1SlV0X09aMnZZZUdKRWkwODVLdjlvTmtKOWNobmlKdlBvT3VTajhnYUFTR05hUzFTS2Vsc1gwX2pmb2FF?oc=5", "external_url": "https://news.google.com/rss/articles/CBMia0FVX3lxTFBxTm5UWlFEUTl5MENWWmZpNUEzV19NUzhMRWRNc2p1ckJSUEpMTEF1SlV0X09aMnZZZUdKRWkwODVLdjlvTmtKOWNobmlKdlBvT3VTajhnYUFTR05hUzFTS2Vsc1gwX2pmb2FF?oc=5", "title": "Altri Sgps SA (ALTR)", "content_text": "Altri Sgps SA (ALTR)", "date_published": "2017-06-13T08:59:17+00:00", "authors": [{"name": "ADVFN"}], "tags": ["Market update", "ALTR"], "_sharemaestro": {"country": "Portugal", "coverage": "Main company", "market_context": null, "companies": [{"symbol": "ALTR", "name": "Altri, SGPS, S.A.", "sentiment_url": "https://sharemaestro.com/sentiment/6f7fbed2-d7af-4b80-b6a0-d133915d8c46/"}]}}]}